Volume 3, Number 2—June 1997
Synopsis
Hantaviruses: A Global Disease Problem
Connie Schmaljohn*
and Brian Hjelle
and Brian HjelleTable 2
Distinguishing clinical characteristics for HFRS and HPS
| Disease | Pathogens | Distinguishing Characteristics* |
|---|---|---|
| HFRS (moderate-severe) Death rate 1%-15% | HTN, SEO, DOB | hemorrhage +++ azotemia/ proteinuria +++/++++ pulmonary capillary leak +/++ myositis +/+++ conjunctival injection ++/++++ eye pain/myopia ++/++++ |
| HFRS (mild) Death rate <1% | PUU | hemorrhage + azotemia/ proteinuria +/++++ pulmonary capillary leak -/+ myositis + conjunctival injection + eye pain/myopia ++/++++ |
| HPS (prototype) Death rate >40% | SN, NY | hemorrhage + zotemia/ proteinuria + pulmonary capillary leak ++++ myositis - conjunctival injection -/+ eye pain/myopia - |
| HPS (renal variant) Death rate>40% | BAY, BCC, Andes | hemorrhage + azotemia/ proteinuria ++/+++ pulmonary capillary leak +++/++++ myositis ++/++++ conjunctival injection -/++ eye pain/myopia - |
*Minimum/maximum occurrence of the characteristic: - rarely reported;
+ infrequent or mild manifestation; ++, +++, ++++ more frequent and severe manifestation.
